top of page

Mwandishi:

Mhariri:

Dkt. Sospeter M, MD

Dkt. Charles W, MD

9 Juni 2020 09:59:28

Matibabu ya kisukari

Matibabu ya kisukari

Matibabu ya kisukari ni yapi?

Matibabu ya kisukari hutegemea aina ya kisukari ulichonacho endapo ni aina ya 1 au 2

Matibabu ya kisukari aina ya 1

Matibabu ya kisukari aina ya kwanza huwa ni yale ya kutumia sindano yenye homoni ya insulin, insulin hii hutolewa kulingana na uzito wa mtu na dozi yake ya siku huwa kati ya 0.5- 1 IU kwa kila kilo ya uzito na hutumiwa mchanganyiko wa insulin aina mbili, aina ya kwanza ni lente naya pili ni soluble

Mfano mtu mwenye kilo 60 akitumia dozi ya 0.5 IU/Kg manake dozi yake ya siku nzima itakuwa 30IU yaani (0.5 IU/Kg × 60kg = 30 IU)

Kwa jinsi gani unapata dozi ya asubuhi na jioni na utatumia lente kiasi gani na soluble kiasi gani?

Mahesabu huwa ya namna hii, mara baada ya kupata dozi ya siku nzima kama tulivyopata 30 kwa mtu mwenye kilo sitini endapo atatumia 0.5 IU/Kg basi mbili ya tatu ya dozi (2/3×30 IU =20 IU) hutumika asubuhi na moja ya tatu iliyobaki hutumika jioni ( ×30=10)

Tumepata 20 IU asubuhi na 10 IU jioni basi tuangalie asubuhi unatakiwa kutumia lente kiasi gani na soluble kiasi gani?

Mahesabu ni yale yale 2/3 ya dozi nzima ya asubuhi huwa lente na 1/3 ya dozi ya asubuhi huwa soluble.

Dozi ya asubuhi

Sasa tuchukulie kwa dozi yetu ya 20IU ya asubuhi

• Lente itakuwa kiasi gani? (2/3 ×20 IU= 13 IU)

• Soluble itakuwa (1/3×20 IU= 7 IU) au 20-13=7 IU


Dozi ya jioni

2/3 Dozi nzima ya jioni huwa lente na 1/3 ya dozi nzima ya jioni kuwa soluble.

Kwa dozi yetu ya 10IU kama tulivyopata awali

• Lente = (2/3×10 IU=6.66 IU au 7 IU)

• Soluble= (1/3× 10 IU= 3.33 IU au 3 IU)


Mambo ya kukumbuka

Tumeanza kutumia kiwango cha 0.5 IU kwa kila kilo yako yauzito kama dozi ya siku nzima na sio 0.7 au 0.9 au 1 IU kwa kilo kwa sababu zifuatazo;

Ukitumia dozi kubwa ya insulin kwa siku unaweza kusababisha kiwango cha sukari kushuka sana, hali hii inaweza kupelekea kuzimia au kufa endapo matibabu ya haraka hayajafanyika.

Ili kama dozi ya chini isiposhusha sukari kwa kiwango kinachotarajiwa au ulichoshauriwa na daktari wako, dozi ipandishwe kwenda zaidi ya 0.5 kwa kila kilo ya uzito wako

Mwombe ushauri mtaalamu wa kisukari au daktari wako ili akukokotolee dozi sahihi kulingana na uzito wako endapo hujaelewa mahesabu haya. Pia daktari wako atakushauri ni wakati gani wa kuongeza/ kupunguza dozi ya insulin ili iendane na mahitaji ya mwili wakati huo ikiwa inafanya kazi vema kurekebisha kiwango cha sukari kuwa kwenye hali ya kawaida.


Kisukari aina ya Pili


Shirika la dawa na chakula duniani FDA limependekeza matumizi ya dawa za vidonge aina mbili tofauti mara moja kwa siku kukabiliana na sukari kwa mgonjwa wa kisukari aina ya 2. Mchanganyo wa dawa mbili zilizopendekezwa ni dawa kundi la sodium glucose cotransporter na mertformin. Vidonge vinatakiwa vitumike pamoja na mazoezi kwa mtu mwenye kisukari na dawa zinatakiwa zitumiwe asubuhi baada ya kula chakula.

Lengo la matibabu ya kupambana na kupanda kwa sukari ni;

  • Kupunguza hatari ya uharibifu katika mishipa midogo ya damu inayoweza kuathiri utendaji kazi wa Macho na figo

  • Kupunguza hatari ya uhalibifu wa mishipa mikubwa ya damu inayoweza kusababisha magonjwa ya mishipa ya moyo,ubongo, na maeneo ya miguuni

  • Kupunguza madhara ya kimfumo wa fahamu na utendaji kazi wa chembe hai

Imeboreshwa

6 Oktoba 2021 06:49:43

Uly clinic inakushauri siku zote uwasiliane na daktari wako kabla ya kuchukua hatua yoyote dhidi ya afya yako.

Wasiliana na daktari wa ULY clinic kwa kubonyeza 'Pata Tiba' au kwa kupiga namba za simu chini ya tovuti hii.

Rejea za mada hii;

​

  1. Tessier D, Meneilly GS. Diabetes management in the elderly. In: Gerstein HC, ed. Evidence-based diabetes care. Hamilton: BC Decker Inc., 2001, pg. 370–9.

  2. Lipska KJ, De Rekeneire N, Van Ness PH, et al. Identifying dysglycemic states in older adults: Implications of the emerging use of hemoglobin A1c. J Clin Endocrinol Metab 2010;95:5289–95.

  3. Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006;61:1075–81.

  4. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072–7.

  5. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096– 105.

  6. Inzucchi SE, Viscoli CM, Young LH, et al. Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease. Diabetes Care 2016;39:1684–92.

  7. Kronsbein P, Jorgens V, Muhlhauser I, et al. Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes. Lancet 1988;2:1407–11.

  8. Wilson W, Pratt C. The impact of diabetes education and peer support upon weight and glycemic control of elderly persons with NonInsulin Dependent Diabetes Mellitus (NIDDM). Am J Public Health 1987;77:634–5.

  9. Braun AK, Kubiak T, Kuntsche J, et al. SGS: A structured treatment and teaching programme for older patients with diabetes mellitus–a prospective randomised controlled multi-centre trial. Age Ageing 2009;38:390–6.

  10.  Fagan PJ, Schuster AB, Boyd C, et al. Chronic care improvement in primary care: Evaluation of an integrated pay-for-performance and practice-based care coordination program among elderly patients with diabetes. Health Serv Res 2010;45:1763–82.

  11. McGovern MP, Williams DJ, Hannaford PC, et al. Introduction of a new incentive and target-based contract for family physicians in the UK: Good for older patients with diabetes but less good for women? Diabet Med 2008;25:1083–9.

  12. Maar MA, Manitowabi D, Gzik D, et al. Serious complications for patients, care providers and policy makers: Tackling the structural violence of First Nations people living with diabetes in Canada. Int Indigenous Policy J 2011;21:http://ir.lib.uwo.ca/iipj/vol2/iss1/6. Article 6.Imechukuliwa 05.06.2020

  13.  Jacklin KM, Henderson RI, Green ME, et al. Health care experiences of Indigenous people living with type 2 diabetes in Canada. CMAJ 2017;189:E106– 12.

  14. Chandler MJ, Lalonde C. Cultural continuity as a protective factor against suicide in First Nations Youth. Horizons 2008;10:68–72.

  15. Oster RT, Grier A, Lightning R, Mayan MJ, Toth EL. Cultural continuity, traditional Indigenous language, and diabetes in Alberta First Nations: A mixed methods study. Int J Equity Health 2014;13:92. doi:10.1186/s12939-014- 0092-4.

  16. Truth and Reconciliation Commission of Canada. Truth and reconcilliation commission of Canada: calls to action. Winnipeg, MB: Truth and Reconciliation Commission of Canada 2012. 2015. http://www.trc.ca/websites/ trcinstitution/File/2015/Findings/Calls_to_Action_English2.pdf.Imechukuliwa 05.06.2020

  17.  Yu CH, Zinman B. Type 2 diabetes and impaired glucose tolerance in aboriginal populations: A global perspective. Diabetes Res Clin Pract 2007;78:159– 70.

  18. Gracey M, King M. Indigenous health part 1: Determinants and disease patterns. Lancet 2009;374:65–75.

  19. Chronic Disease Surveillance and Monitoring Division, Centre for Chronic Disease Prevention and Control. Diabetes in Canada: Facts and figures from a public health perspective. Ottawa, ON: Public Health Agency of Canada, 2011 http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts -figures-faits-chiffres-2011/index-eng.php. Imechukuliwa 05.06.2020

  20. Turin TC, Saad N, Jun M, et al. Lifetime risk of diabetes among first nations and non-first nations people. CMAJ 2016;188:1147–53.

  21. Singer J, Putulik Kidlapik C, Martin B, et al. Food consumption, obesity and abnormal glycaemic control in a Canadian Inuit community. Clin Obes 2014;4:316– 23.

​

bottom of page